A groundbreaking study by the University of Texas Health Science Center at San Antonio (UT Health San Antonio) reveals that combining a smartphone app with medication significantly reduces opioid use and increases treatment retention for patients battling opioid use disorder (OUD). The research, published in JAMA Network Open, underscores the potential of mobile health solutions in augmenting traditional treatments for opioid addiction.
The study, which involved 600 underserved patients, found that those who used the WEconnect Health app – a tool incorporating contingency management (CM) therapy and peer recovery support – reduced their opioid use by 35% compared to patients receiving only medication. Additionally, patients using the app remained in treatment for an average of 290 days, nearly 19% longer than those relying solely on medication.
Opioid use disorder remains a major public health crisis in the United States, responsible for thousands of deaths annually and a staggering $968.9 billion in societal costs. While medications such as methadone, buprenorphine, and naltrexone are effective in reducing opioid-related harm, many patients struggle with maintaining sobriety and adhering to treatment.
Historically, contingency management (CM) – which incentivizes positive treatment milestones – has proven effective in enhancing treatment outcomes. However, traditional CM has required frequent in-person clinic visits, creating barriers such as transportation issues, clinic accessibility, and, more recently, reluctance due to the COVID-19 pandemic.
The WEconnect Health app seeks to address these limitations by offering a flexible, user-friendly platform that combines evidence-based CM with peer support services. Patients can set daily goals, track their progress, and receive incentives for meeting treatment targets. The app also connects users with certified peer counselors and online meetings, providing support beyond traditional clinic hours.
“This study highlights how smartphone-based CM could be a game-changer for underserved populations,” said Elise Marino, PhD, director of research operations at UT Health San Antonio’s Be Well Institute on Substance Use and Related Disorders. “The app not only enhances treatment outcomes but also empowers patients to manage their recovery on their own terms.”
Between November 2020 and November 2023, the cohort study tracked the progress of 600 uninsured or underinsured patients enrolled in opioid treatment programs across Texas. The results showed that patients using the app-based CM had an average of 8.4 days of opioid use by the end of treatment, compared to 12 days for those receiving medication alone. Furthermore, the retention rate for the app users was significantly higher, with a mean treatment duration of 290.2 days versus 236.1 days for the medication-only group.
“These findings suggest that augmenting medication with smartphone-based CM can lead to better treatment engagement and reduced opioid use,” said Marino. “This approach could play a crucial role in supporting the growing number of patients who need access to effective and accessible addiction treatment.”
With opioid use disorder continuing to impact millions of Americans, innovative solutions like the WEconnect app are essential in providing accessible, effective care. The study’s findings are an important step toward expanding digital health tools in addiction treatment, particularly for those who face barriers to in-person care.
The research also opens the door to further exploration of mobile health applications as a means of enhancing clinical care, increasing engagement, and reducing opioid use in underserved communities. As the healthcare system continues to evolve, the integration of technology could play a pivotal role in combating the opioid crisis.
Read more:
- New Oral Migraine Drug, Atogepant, Offers Swift Relief For Sufferers
- Unseen And Ubiquitous: How Microplastics Are Impacting Human Health
- Can The Heart Heal Itself? Scientists Reveal Surprising New Findings
